Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.43 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9896517 | 0.86 | PTGS1 (0.57) | PTGS2PTGS1CYP2C9AKR1C2AKR1C3 | |
| SCHEMBL9898533 | 0.85 | ESR1 (0.59) | EPHX2CYP2C9CYP2C19CYP2J2ESR2 | |
| SCHEMBL9895000 | 0.84 | SLC1A1 (0.48) | EPHX2PTGS2CYP2C9AKR1C3CCR5 | |
| SCHEMBL9895935 | 0.84 | VNN1 (0.45) | EPHX2PTGS2PTGS1CA2 | |
| SCHEMBL7847559 | 0.82 | EPHX2 (0.49) | EPHX2PTGS2PTGS1ESR2 | |
| SCHEMBL9898689 | 0.82 | EPHX2 (0.43) | EPHX2CYP2C9CYP2C19CYP2J2ESR2 | |
| SCHEMBL9895954 | 0.80 | PTGS2 (0.42) | EPHX2PTGS2PTGS1CA2AKR1C2 | |
| SCHEMBL4664796 | 0.80 | PPARA (0.56) | EPHX2PTGS2PTGS1CYP2C9CYP2C19 | |
| SCHEMBL29174149 | 0.78 | LDHA (0.59) | PTGS2PTGS1CYP2C9CYP2C19 | |
| SCHEMBL4482850 | 0.77 | AKR1C3 (0.47) | EPHX2PTGS1AKR1C2AKR1C1AKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149718-A1 | Amido Compounds | BROTHERTON-PLEISS CHRISTINE E (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149718-A1 | Amido Compounds | P2RX7, P2RX3, P2RX2 | EPHX2 1765/4885PTGS2 1485/4885PTGS1 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.